The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Optimizing induction and pretransplant consolidation for myeloma: Results of Myeloma XI, a phase III trial comparing different IMiDs.
Charlotte Pawlyn
Honoraria - Celgene
Other Remuneration - Celgene; Janssen
Faith E Davies
Consultant or Advisory Role - Celgene; Janssen
Honoraria - Celgene; Janssen
Other Remuneration - Celgene; Janssen
David A. Cairns
No relevant relationships to disclose
Walter Gregory
Honoraria - Celgene
Ana Quartilho
No relevant relationships to disclose
Jacqueline Ouzman
No relevant relationships to disclose
Helen C Howard
No relevant relationships to disclose
Corinne Collett
No relevant relationships to disclose
Jindriska Lindsay
Honoraria - Celgene
Other Remuneration - Celgene
Gordon Cook
Honoraria - Celgene; Janssen
Other Remuneration - Celgene; Janssen
Donald Milligan
No relevant relationships to disclose
Claire Chapman
No relevant relationships to disclose
David Allotey
Other Remuneration - Celgene
Roger G. Owen
Honoraria - Celgene; Janssen
Other Remuneration - Celgene; Janssen
Mark Drayson
No relevant relationships to disclose
Nigel Russell
No relevant relationships to disclose
Graham H. Jackson
Honoraria - Celgene; Janssen
Gareth J Morgan
Consultant or Advisory Role - Celgene; Janssen
Honoraria - Celgene; Janssen
Other Remuneration - Celgene; Janssen